BTI.V - Bioasis Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1600
0.0000 (0.00%)
At close: 2:47PM EDT
Stock chart is not supported by your current browser
Previous Close0.1600
Open0.1700
Bid0.1450 x 0
Ask0.1600 x 0
Day's Range0.1600 - 0.1700
52 Week Range0.1400 - 0.3500
Volume29,500
Avg. Volume36,382
Market Cap10.161M
Beta (5Y Monthly)0.39
PE Ratio (TTM)N/A
EPS (TTM)-0.0630
Earnings DateJan. 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Bioasis Completes Redemption of 15% Unsecured Debentures With Unanimous Debentureholder Approval

    BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis") a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has completed its previously announced redemption all of its outstanding 15% unsecured debentures issued November 8, 2019 (the "Debentures") at a price equal to 110% of the principal amount of the Debentures (the "Redemption Price"). 100% of the holders of Debentures (the "Debentureholders") agreed to participate in the transaction.

  • Business Wire

    Bioasis Announces Shares for Debt Transaction

    Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to satisfy its obligation to pay $28,076.55 in interest to the holders of its 15% unsecured debentures issued November 8, 2019 (the "Debentures") as of March 31, 2020 by issuing 155,980 common shares of the Company. The common shares will be issued at a deemed price of $0.18 per share in full satisfaction of the March 31 interest payment obligation in accordance with the terms of the Debentures. The Company chose to settle the interest through the issuance of common shares in order to preserve the amount of cash available to fund ongoing operations while it continues to pursue additional financing opportunities, including potential partnerships.

  • Business Wire

    Bioasis Announces Proposed Redemption of 15% Unsecured Debentures

    BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to redeem all of its outstanding 15% unsecured debentures issued November 8, 2019 (the "Debentures") at a price equal to 110% of the principal amount of the Debentures (the "Redemption Price"). The Company intends to settle the Redemption Price through the issuance of common shares at a price of $0.20 per share. The aggregate outstanding principal amount of the Debentures is $750,765 and therefore the aggregate Redemption Price is $825,841.50 and the number of common shares to be issued in settlement of the Redemption Price is 4,129,207.

  • Business Wire

    Bioasis Technologies Announces the Appointment of Dr. May Orfali to the Position of Consultant Chief Medical Officer

    Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced today the appointment of Dr. May Orfali to the position of Consultant Chief Medical Officer, effective immediately. In this position, Dr. Orfali replaces Dr. Jose Iglesias, who has recently accepted a full-time position at another company. We thank Dr. Iglesias for his contributions to Bioasis to date.

  • CNW Group

    Growth Company Investor Presentations Now Available for On-Demand Viewing

    Growth Company Investor Presentations Now Available for On-Demand Viewing

  • CNW Group

    Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

    Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

  • Investors Who Bought Bioasis Technologies (CVE:BTI) Shares Three Years Ago Are Now Down 83%
    Simply Wall St.

    Investors Who Bought Bioasis Technologies (CVE:BTI) Shares Three Years Ago Are Now Down 83%

    Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So consider, for a...